Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems

谷氨酰胺 免疫系统 肿瘤微环境 癌症研究 生物 癌细胞 药理学 免疫学 癌症 生物化学 氨基酸 遗传学
作者
Yumi Yokoyama,Robert A. Wild,Thomas M. Estok
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:21 (10): 1561-1572 被引量:6
标识
DOI:10.1158/1535-7163.mct-22-0282
摘要

Glutamine is a conditionally essential amino acid consumed by rapidly proliferating cancer cells, which deprives the same fuel from immune cells and contributes to tumor immune evasion. As such, the broad antagonism of glutamine in tumors and the tumor microenvironment may lead to direct antitumor activity and stimulation of antitumoral immune responses. DRP-104 (sirpiglenastat) was designed as a novel prodrug of the broad-acting glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON). DRP-104 is an inactive form that is preferentially converted to DON within tumors. Metabolomic profiling of tumors treated with DRP-104 revealed widespread changes indicative of the disruption of tumor anabolism and canonical cancer metabolism pathways; including altered glutamine metabolism while several immunosuppressive metabolites were decreased. Gene expression profiling revealed broad immunological modulation, confirmed by flow cytometry indicating that DRP-104 treatment resulted in substantial and broad changes in various immune cell infiltrates, such as increased TIL, T, NK, and NK T cells. Functionally, T cells became more proliferative and less exhausted; tumor-associated macrophages were polarized to the M1 phenotype; MDSCs and protumorigenic proteins were decreased in TME. Finally, DRP-104 demonstrated significant antitumor activity as a monotherapy, which was further enhanced in combination with checkpoint blockade therapies, leading to improved survival and long-term durable cures. In summary, DRP-104 broadly remodels the tumor microenvironment by inducing extensive tumor metabolism effects and enhancing the infiltration and function of multiple immune cells distinct from those obtained by checkpoint inhibitor therapy. This unique mechanism of action supports the ongoing clinical development of DRP-104 alone and in combination with checkpoint inhibitors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在水一方应助焦米棍采纳,获得10
2秒前
2秒前
3秒前
星辰大海应助fei菲飞采纳,获得10
4秒前
Monster完成签到,获得积分10
4秒前
yyyy完成签到,获得积分10
5秒前
7秒前
美丽雪冥完成签到 ,获得积分10
7秒前
包容丹云完成签到,获得积分10
8秒前
11112321321完成签到 ,获得积分10
9秒前
蓝色如你如我完成签到,获得积分10
10秒前
真实的火车完成签到,获得积分10
11秒前
暗栀发布了新的文献求助10
11秒前
星星完成签到,获得积分10
13秒前
14秒前
巫马沛春完成签到,获得积分10
14秒前
丰富的宛亦完成签到 ,获得积分10
16秒前
小黑应助热心不凡采纳,获得100
16秒前
无限的夜蕾完成签到,获得积分10
19秒前
戴维少尉完成签到,获得积分10
20秒前
Trista完成签到,获得积分10
21秒前
儒雅棒球完成签到,获得积分10
22秒前
懒懒洋洋洋完成签到 ,获得积分10
23秒前
24秒前
华北走地鸡完成签到,获得积分10
26秒前
27秒前
撒啊完成签到,获得积分10
27秒前
心灵美诗霜完成签到 ,获得积分0
28秒前
机智傀斗完成签到,获得积分10
28秒前
WRWRWR完成签到,获得积分10
29秒前
Cynthia完成签到 ,获得积分10
29秒前
30秒前
清爽达完成签到 ,获得积分10
30秒前
跳跃凡桃发布了新的文献求助30
31秒前
欢呼芒果发布了新的文献求助10
32秒前
岩追研完成签到,获得积分10
33秒前
33秒前
eternity136应助Qing采纳,获得20
34秒前
37秒前
warming发布了新的文献求助10
37秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 720
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3566813
求助须知:如何正确求助?哪些是违规求助? 3139569
关于积分的说明 9432078
捐赠科研通 2840387
什么是DOI,文献DOI怎么找? 1560995
邀请新用户注册赠送积分活动 730141
科研通“疑难数据库(出版商)”最低求助积分说明 717855